Recent developments in the biology of respiratory syncytial virus: Are vaccines and new treatments just round the corner?

Current Opinion in Microbiology

Volumn 2, Issue 4, 1999, Pages 410-414

  Hussell, Tracy ^a   Openshaw, Peter ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; DNA VACCINE;

BRONCHIOLITIS; DEVELOPING COUNTRY; GENETIC ENGINEERING; HUMAN; IMMUNOPATHOGENESIS; MOLECULAR CLONING; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW;

EID: 0033178776     PISSN: 13695274     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1369-5274(99)80072-1     Document Type: Review

References (46)

1. Falsey AR, Walsh EE: Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in the institutionalized elderly. Vaccine 1997, 15:1130-1132.
2. Nicholson KG: Impact of influenza and respiratory syncytial virus on mortality in England and Wales from January 1975 to December 1990. Epidemiol Infect 1996, 116:51-63.
3. Whimbey E, Champlin RE, Englund JA, Mirza NQ, Piedra PA, Goodrich JM, Przepiorka D, Luna MA, Morice RC, Neumann JL et al.: Combination therapy with aerosolized ribavirin and intravenous immunoglobulin for respiratory syncytial virus disease in adult bone marrow transplant recipients. Bone Marrow Transplant 1995, 16:393-399.
4. Crowe JEJ: Immune responses of infants to infection with respiratory viruses and live attenuated respiratory virus candidate vaccines. Vaccine 1998, 16:1423-1432.
5. Bembridge GP, Garcia BR, Lopez JA, Melero JA, Taylor G: Subcellular site of expression and route of vaccination influence pulmonary eosinophilia following respiratory syncytial virus challenge in BALB/c mice sensitized to the attachment G protein. J Immunol 1998, 161:2473-2480. Mice immunised with recombinant vaccinia encoding membrane-bound or secreted forms of protein G were challenged with respiratory syncytial virus (RSV). The secreted form of protein G induced more marked lung eosinophilia, but eosinophilia was not seen in mice vaccinated intraperitoneally.
6. Johnson TR, Johnson JE, Roberts SR, Wertz GW, Parker RA, Graham BS: Priming with secreted glycoprotein G of respiratory syncytial virus (RSV) augments interleukin-5 production and tissue eosinophilia after RSV challenge. J Virol 1998, 72:2871-2880. Secreted protein G made by recombinant vaccinia primes for more severe illness during respiratory syncytial virus (RSV) challenge, with greater lung eosinophilia and interleukin-5 production.
7. + T lymphocytes downregulate T helper cell type 2 cytokine secretion and pulmonary eosinophilia during experimental murine respiratory syncytial virus infection. J Exp Med 1997, 186:421-432.
8. + T-cells control Th2-driven pathology during pulmonary respiratory syncytial virus infection. Eur J Immunol 1997, 27:3341-3349.
9. Cane PA, Pringle CR: Evolution of subgroup A respiratory syncytial virus: Evidence for progressive accumulation of amino acid changes in the attachment protein. J Virol 1995, 69:2918-2925.
10. Peret TC, Hall CB, Schnabel KC, Golub JA, Anderson LJ: Circulation patterns of genetically distinct group A and B strains of human respiratory syncytial virus in a community. J Gen Virol 1998, 79:2221-2229.
11. Sullender WM, Mufson MA, Prince GA, Anderson LJ, Wertz GW: Antigenic and genetic diversity among the attachment proteins of group A respiratory syncytial viruses that have caused repeat infections in children. J Infect Dis 1998, 178:925-932.
12. Valdes O, Martinez I, Valdivia A, Cancio R, Savon C, Goyenechea A, Melero JA: Unusual antigenic and genetic characteristics of human respiratory syncytial viruses isolated in Cuba. J Virol 1998, 72:7589-7592.
13. Collins PL, Hill MG, Camargo E, Grosfeld H, Chanock RM, Murphy BR: Production of infectious human respiratory syncytial virus from cloned cDNA confirms an essential role for the transcription elongation factor from the 5′ proximal open reading frame of the M2 mRNA in gene expression and provides a capability for vaccine development. Proc Natl Acad Sci USA 1995, 92:11563-11567.
14. Jin H, Clarke D, Zhou HZ, Cheng X, Coelingh K, Bryant M, Li S: Recombinant human respiratory syncytial virus (RSV) from cDNA and construction of subgroup A and B chimeric RSV. Virology 1998, 251:206-214. Infectious human RSV was produced from a cDNA clone that contains 15,222 nucleotides of RSV genome derived from the A2 strain of subgroup A. Heterotypic virus with surface protein G expression from bovine RSV was also produced.
15. Kahn JS, Schnell MJ, Buonocore L, Rose JK: Recombinant vesicular stomatitis virus expressing respiratory syncytial virus (RSV) glycoproteins: RSV fusion protein can mediate infection and cell fusion. Virology 1999, 254:81-91. This genetically modified vector vesicular stomatitis virus (VSV) vector can package RSV surface proteins. This recombinant virus could not have arisen in nature. The potential for producing candidate vaccines is exciting, but needs to be carefully balanced against the potential risks of producing novel viruses.
16. Whitehead SS, Firestone CY, Collins PL, Murphy BR: A single nucleotide substitution in the transcription start signal of the M2 gene of respiratory syncytial virus vaccine candidate cpts248/404 is the major determinant of the temperature-sensitive and attenuation phenotypes. Virology 1998, 247:232-239.
17. Bukreyev A, Whitehead SS, Bukreyeva N, Murphy B, Collins PL: Interferon gamma expressed by a recombinant respiratory syncytial virus attenuates virus replication in mice without compromising immunogenicity. Proc Natl Acad Sci USA 1999, 96:2367-2372. A genetically engineered novel recombinant respiratory syncytial virus (RSV) encoding murine interferon-gamma limits its own replication in the respiratory tract, but still induces an excellent protective immune response.
18. Teng MN, Collins PL: Identification of the respiratory syncytial virus proteins required for formation and passage of helper-dependent infectious particles. J Virol 1998, 72:5707-5716.
19. Sparer TE, Matthews S, Hussell T, Rae AJ, Garcia-Barreno B, Melero JA, Openshaw PJM: Eliminating a region of respiratory syncytial virus attachment protein allows induction of protective immunity without vaccine-enhanced lung eosinophilia. J Exp Med 1998, 187:1921-1926. These studies used viruses containing frameshifts that altered the carboxyterminus of the G protein, and identified residues 193-205 to be responsible for G protein induced weight loss and lung eosinophilia. This region, however, was not necessary for induction of protective immunity.
20. Tebbey PW, Hagen M, Hancock GE: Atypical pulmonary eosinophilia is mediated by a specific amino acid sequence of the attachment (G) protein of respiratory syncytial virus. J Exp Med 1998, 188:1967-1972.
21. + T cells or interferon-gamma rendered C57BL/6 (but not BALB.K) mice susceptible to eosinophilia.
22. Roman M, Calhoun WJ, Hinton KL, Avendano LF, Simon V, Escobar AM, Gaggero A, Diaz PV: Respiratory syncytial virus infection in infants is associated with predominant Th-2-like response. Am J Respir Crit Care Med 1997, 156:190-195.
23. Olszewska PB, Casola A, Saito T, Alam R, Crowe SE, Mei F, Ogra PL, Garofalo RP: Cell specific expression of RANTES, MCP-1, and MIP-1α by lower airway epithelial cells and eosinophils infected with respiratory syncytial virus. J Virol 1998, 72:4756-4764.
24. Olszewska PB, Casola A, Saito T, Alam R, Crowe SE, Mei F, Ogra PL, Garofalo RP: Cell-specific expression of RANTES, MCP-1, and MIP-1alpha by lower airway epithelial cells and eosinophils infected with respiratory syncytial virus. J Virol 1998, 72:4756-4764.
25. Sheeran P, Jafri H, Carubelli C, Saavedra J, Johnson C, Krisher K, Sanchez PJ, Ramilo O: Elevated cytokine concentrations in the nasopharyngeal and tracheal secretions of children with respiratory syncytial virus disease. Pediatr Infect Dis J 1999, 18:115-122.
26. De WW, Twilhaar WN, Kimpen JL: T cell subset analysis in peripheral blood of children with RSV bronchiolitis. Scand J Infect Dis 1998, 30:77-80.
27. Langedijk JP, de Groot BL, Berendsen HJ, van Oirschot JT: Structural homology of the central conserved region of the attachment protein G of respiratory syncytial virus with the fourth subdomain of 55 kDa tumor necrosis factor receptor. Virology 1998, 243:293-302. The highly conserved cystine-rich ectodomain of the respiratory syncytial virus (RSV) G protein is flanked by two mucin-like regions. This paper describes a structural homology between this conserved domain and the fourth subdomain of the 55 kDa tumour necrosis factor receptor.
28. Dudas RA, Karron RA: Respiratory syncytial virus vaccines. Clin Microbiol Rev 1998, 11:430-439.
29. Groothuis JR, King SJ, Hogerman DA, Paradiso PR, Simoes EA: Safety and immunogenicity of a purified F protein respiratory syncytial virus (PFP-2) vaccine in seropositive children with bronchopulmonary dysplasia. J Infect Dis 1998, 177:467-469.
30. Piedra PA, Grace S, Jewell A, Spinelli S, Hogerman DA, Malinoski F, Hiatt PW: Sequential annual administration of purified fusion protein vaccine against respiratory syncytial virus in children with cystic fibrosis. Pediatr Infect Dis J 1998, 17:217-224.
31. Englund J, Glezen WP, Piedra PA: Maternal immunization against viral disease. Vaccine 1998, 16:1456-1463.
32. Whitehead SS, Juhasz K, Firestone CY, Collins PL, Murphy BR: Recombinant respiratory syncytial virus (RSV) bearing a set of mutations from cold-passaged RSV is attenuated in chimpanzees. J Virol 1998, 72:4467-4471.
33. Li X, Sambhara S, Li CX, Ewasyshyn M, Parrington M, Caterini J, James O, Cates G, Du RP, Klein M: Protection against respiratory syncytial virus infection by DNA immunization. J Exp Med 1998, 188:681-688. Plasmid DNA expressing fusion protein (F) induces neutralising antibody and cytotoxic T lymphocytes (CTL) in mice, protects against re-infection and could switch an established Th2 response to Th1.
34. Simoes EA, Sondheimer HM, Top-FH J, Meissner HC, Welliver RC, Kramer AA, Groothuis JR: Respiratory syncytial virus immune globulin for prophylaxis against respiratory syncytial virus disease in infants and children with congenital heart disease. J Pediatr 1998, 133:492-499.
35. The IMpact-RSV Study Group: Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998, 102:531-537.
36. Crowe-JE J, Gilmour PS, Murphy BR, Chanock RM, Duan L, Pomerantz RJ, Pilkington GR: Isolation of a second recombinant human respiratory syncytial virus monoclonal antibody fragment (Fab RSVF2-5) that exhibits therapeutic efficacy in vivo. J Infect Dis 1998, 177:1073-1076.
37. Thomas LH, Cook RS, Wyld SG, Furze JM, Taylor G: Passive protection of gnotobiotic calves using monoclonal antibodies directed at different epitopes on the fusion protein of bovine respiratory syncytial virus. J Infect Dis 1998, 177:874-880.
38. O'Shea TM, Sevick MA, Givner LB: Costs and benefits of respiratory syncytial virus immunoglobulin to prevent hospitalization for lower respiratory tract illness in very low birth weight infants. Pediatr Infect Dis J 1998, 17:587-593.
39. Fujiwara M, Ashida N, Okamoto M, Mizuta T, Ide T, Hanasaki Y, Katsuura K, Sawada H, Shigeta S, Konno K et al.: RD6-2198, a novel betain-type fluoroalkylated oligomer, inhibits the replications of human immunodeficiency virus type 1 and other enveloped viruses. Antiviral Res 1998, 38:141-149.
40. Player MR, Barnard DL, Torrence PF: Potent inhibition of respiratory syncytial virus replication using a 2-5A-antisense chimera targeted to signals within the virus genomic RNA. Proc Natl Acad Sci USA 1998, 95:8874-8879. Interferon induces 2-5A, which activates RNAase L that degrades viral RNA. Chemical conjugation of 2-5A to an antisense oligonucleotide was used to target RNAase L to the respiratory syncytial virus (RSV) RNA and cause its selective destruction. An antisense chimera (NIH351) was much more potent than ribavirin against RSV.
41. O'Donnell DR, Openshaw PJM: Anaphylactic sensitisation to aeroantigen during respiratory virus infection. Clin Exp Allergy 1998, 28:1501-1508.
42. Robinson PJ, Hegele RG, Schellenberg RR: Allergic sensitization increases airway reactivity in guinea pigs with respiratory syncytial virus bronchiolitis. J Allergy Clin Immunol 1997, 100:492-498.
43. Prescott SL, Macaubas C, Smallacombe T, Holt BJ, Sly PD, Holt PG: Development of allergen-specific T-cell memory in atopic and normal children. Lancet 1999, 353:196-200.
44. Bodner C, Godden D, Seaton A: Family size, childhood infections and atopic diseases. The Aberdeen WHEASE Group. Thorax 1998, 53:28-32.
45. Thomas LH, Friedland JS, Sharland M, Becker S: Respiratory syncytial virus-induced RANTES production from human bronchial epithelial cells is dependent on nuclear factor-kappa B nuclear binding and is inhibited by adenovirus-mediated expression of inhibitor of kappa B alpha. J Immunol 1998, 161:1007-1016.
46. Jamaluddin M, Casola A, Garofalo RP, Han Y, Elliott T, Ogra PL, Brasier AR: The major component of I kappa B alpha proteolysis occurs independently of the proteasome pathway in respiratory syncytial virus-infected pulmonary epithelial cells. J Virol 1998, 72:4849-4857.